Mercer Global Advisors Inc. ADV Sells 4,036 Shares of Amgen Inc. (NASDAQ:AMGN)

Mercer Global Advisors Inc. ADV trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 7.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,727 shares of the medical research company’s stock after selling 4,036 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in Amgen were worth $12,852,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of AMGN. Davidson Capital Management Inc. increased its stake in Amgen by 8.4% in the second quarter. Davidson Capital Management Inc. now owns 5,146 shares of the medical research company’s stock valued at $1,254,000 after purchasing an additional 400 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Amgen by 0.3% during the second quarter. Principal Financial Group Inc. now owns 715,348 shares of the medical research company’s stock worth $174,366,000 after acquiring an additional 2,215 shares in the last quarter. Cibc World Markets Corp increased its position in shares of Amgen by 11.2% during the second quarter. Cibc World Markets Corp now owns 237,832 shares of the medical research company’s stock worth $57,972,000 after acquiring an additional 23,908 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its position in shares of Amgen by 4.9% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 83,687 shares of the medical research company’s stock worth $20,399,000 after acquiring an additional 3,938 shares in the last quarter. Finally, MCF Advisors LLC increased its position in shares of Amgen by 31.7% during the second quarter. MCF Advisors LLC now owns 1,801 shares of the medical research company’s stock worth $439,000 after acquiring an additional 433 shares in the last quarter. 74.73% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts have recently issued reports on AMGN shares. Zacks Investment Research raised shares of Amgen from a “sell” rating to a “hold” rating and set a $255.00 price objective for the company in a research report on Tuesday, June 29th. Oppenheimer increased their price target on shares of Amgen from $272.00 to $277.00 and gave the company an “outperform” rating in a research note on Monday, June 7th. BMO Capital Markets increased their price target on shares of Amgen from $296.00 to $301.00 and gave the company an “outperform” rating in a research note on Monday, May 31st. Morgan Stanley cut shares of Amgen from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $280.00 to $251.00 in a research note on Tuesday, September 7th. Finally, Mizuho assumed coverage on shares of Amgen in a research note on Friday, September 10th. They set a “hold” rating and a $222.00 target price for the company. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, Amgen has an average rating of “Hold” and an average price target of $249.70.

AMGN opened at $216.78 on Wednesday. The company’s 50 day moving average is $232.74 and its 200-day moving average is $240.06. The company has a current ratio of 1.31, a quick ratio of 1.03 and a debt-to-equity ratio of 3.45. Amgen Inc. has a 1-year low of $210.28 and a 1-year high of $276.69. The company has a market cap of $123.10 billion, a P/E ratio of 21.98, a PEG ratio of 1.55 and a beta of 0.68.

Amgen (NASDAQ:AMGN) last posted its earnings results on Monday, August 2nd. The medical research company reported $4.38 EPS for the quarter, topping the consensus estimate of $4.09 by $0.29. Amgen had a net margin of 22.55% and a return on equity of 99.85%. The business had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $6.43 billion. On average, equities analysts forecast that Amgen Inc. will post 16.41 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 8th. Stockholders of record on Tuesday, August 17th were given a $1.76 dividend. The ex-dividend date of this dividend was Monday, August 16th. This represents a $7.04 dividend on an annualized basis and a dividend yield of 3.25%. Amgen’s dividend payout ratio (DPR) is currently 42.41%.

About Amgen

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.

Further Reading: Understanding Relative Strength Index

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.